NCT03423810View on ClinicalTrials.gov

Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

January 30, 2020

Study Completion Date

January 30, 2020

Conditions
Polycystic Kidney Diseases
Interventions
DRUG

Hydralazine

Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT03423810 - Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients | Biotech Hunter | Biotech Hunter